round

About Us

Our Mission

Attention Labs is dedicated to advancing drug discovery for neuropsychiatric conditions like ADHD. Focusing on patients unresponsive to traditional treatments; our pioneering AI/ML platform identifies novel compounds to address unmet clinical needs.

Why ADHD?

ADHD affects millions globally, causing significant economic and personal burdens. Despite its prevalence, the market has seen little innovation in decades. Our breakthrough molecule, ATTN001, offers a novel approach to addressing this challenge. We are poised to disrupt a market projected to reach $45 billion by 2034.

img
pipeline_1

Pipeline

New Chemical Entities with improved safety, efficacy, dosing and convenience.

Oral Dopamine D2 receptor agonist

Orally bioavailable, non-stimulant, with high brain penetration. Indication: ADHD

  • Discovery
  • Pre Clinic
  • Ind Enabling
  • Phase 1
  • Phase 2

Team

Our team combines expertise in neuroscience, AI/ML, and business development to bring innovative solutions to market

Temitiop

Temitope Sobodu PhD

Neuropharmcologist
Founder/CEO

  • boston
  • harvard
  • sanofi
  • pfizer
Jack

Jack Rudrum PhD

Bioengineer
CTO

  • Mit
  • western australia
Nick

Nick Castoria MBA

CBO

  • harvard business
  • ys
Abhishek

Abhishek Poddar PhD

Molecular Biologist
CSO

  • harvard
  • Toledo
  • MGH

Our Partners

We collaborate with leading academic and financial institutions, as well as biotech innovators, to drive the success of our mission. Join us in advancing the frontier of cognitive health by partnering with Attention Labs.

Partners
Partners
Partners
Partners
map map

Contact Us

Are you an investor, academic, or enthusiast interested in our science, please reach out via this form.